In the Claims:

Claims 2 and 3 are cancelled.
Claims 1, 4-15 are pending

1) (currently amended) A method of treating a human patient with a form of cancer selected from the group consisting of leukemia, lymphoma and myeloma who has received an allogeneic hematopoietic cell transplant ~~by controlling a GVL effect~~, comprising administering to said patient an amount of beclomethasone 17, 21-diproprionate, the amount being capable of maintaining a graft-versus-leukemia reaction and ~~effective to prevent or reduce symptoms of GVHD wherein the administration leads to less prednisone exposure while maintaining a GVL reaction effective to~~ eliminating or reducing the number of cancer cells in the blood of said patient.

2) (cancelled)

3) (cancelled)

4) (previously presented) The method of claim 1, wherein the beclomethasone 17, 21-diproprionate is administered orally at a dosage of between about 0.1 mg per day to about 8 mg per day.

5) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered orally at a dosage of between about 2 mg per day to about 4 mg per day.

6) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered orally from

7) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered in combination with prednisone or prednisolone at a concentration of at least 1 mg/kg body weight/day.

8) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is formulated for oral administration in the form of a pill, tablet, capsule or microsphere.

9) (previously presented) The method of claim 8 wherein the beclomethasone 17, 21-diproprionate is formulated such that the pill, microsphere, or capsule dissolves in the stomach, small intestine or colon.

10) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is formulated for oral administration in the form of an emulsion.

11) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered following infusion of the hematopoietic cells.

12) (previously presented) The method of claim 1 wherein administration of the beclomethasone 17, 21-diproprionate ceases after 80 days following infusion of the hematopoietic cells.

13) (previously presented) The method of claim 1 wherein the patient has received an allogeneic bone marrow transplant.

14) (previously presented) The method of claim 1 wherein the patient has received an allogeneic blood transplant.

15) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered in combination with at least one of cyclosporine, methotrexate, tacrolimus, anti-lymphocyte globulin, anti T-cell monoclonal antibodies and anti T-cell immunotoxins.